Research programme: cancer therapeutics - KanceraAlternative Names: HDAC6 inhibitors - Kancera
Latest Information Update: 09 Sep 2016
At a glance
- Originator Kancera
- Class Antineoplastics
- Mechanism of Action HDAC6 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Multiple myeloma; Solid tumours
Most Recent Events
- 09 Sep 2016 Early research in Solid tumours in Sweden (Parenteral) before September 2016 (Kancera Pipeline, September 2016)
- 09 Sep 2016 Early research in Multiple myeloma in Sweden (Parenteral) before September 2016 (Kancera Pipeline, September 2016)